AUS
NZ
UK
CA
USA
IND
_07_12_2023_11_05_52_936360.jpg)
HICL Infrastructure Plc
HICL Infrastructure Plc (LON:HICL) is a London, United Kingdom based infrastructure investment trust whose entire portfolio includes Public-Private Partnership based infrastructure, Regulated properties as well as Demand based Infrastructure. The companyâs primary objective is to deliver a long term, consistent returns to increase the value held by the shareholders from a varied portfolio of infrastructure investments positioned at the bottom side of the risk spectrum. The companyâs portfolio gives direct access for health to around 10 million people and a direct access to educational institution to around 120,000 students across various age groups. The company also delivers rail operations. Regulated Infrastructure, where its portfolio organizations improve, work and keep up imposing business model foundation where execution gauges and evaluating are dependent upon administrative oversight. Request based framework portfolio organizations are contracted to configuration, account, fabricate, work and keep up foundation where their use decides monetary execution. The Company's venture counsellor is InfraRed Capital Partners Limited.
HICL Price of the stock Performance
As on 6th December 2019, at 01:05 P.M Greenwich Mean Time, while this was being written, HICL Infrastructure Plcâs price of the stock has been reported to be trading on LSE at GBX 159.78 per stock, an increase in the value of 0.49 per cent or GBX 0.78 per stock, in comparison with the last dayâs closing share price, which has been reported to be at GBX 159.00 per stock. At the time of writing, the stock was also trading 8.17 per cent below the 52-week high price at GBX 174.00 per stock, which the companyâs stock achieved on November 08, 2019. While this piece was being written, the market capitalisation of the company was valued at GBP 2.947 billion reportedly, with respect to, the share price of the company at the time of writing.
The beta of the companyâs stock has stood at a value of 0.3180. This enables us to understand the fact that movement in the price of the stock of the company, is less volatile, in comparison with the movement of the comparative benchmark index.
PureTech Health Plc
PureTech Health Plc (LON:PRTC) is a multi-disciplinary Pharmaceuticals, Biotechnology as well as Marijuana products organisation and one of the biggest names in the healthcare space in the world. The company has 2 segments â growth stage business and project phase business. The growth stage business involves businesses whose focus is on development of products that solve healthcare problems in varied markets and project phase business involves businesses that focus on financing, sourcing and creating new product categories and newly created businesses whose technologies and processes are in the process of evaluation.
PRTC Price of the stock Performance
As on 6th December 2019, at 01:10 P.M Greenwich Mean Time, while this was being written, PureTech Health Plcâs price of the stock has been reported to be trading on LSE at GBX 251.00 per stock, a decline in the value of 0.40 per cent or GBX 1.00 per stock, in comparison with the last dayâs closing share price, which has been reported to be at GBX 252.00 per stock. At the time of writing, the stock was also trading 18.24 per cent below the 52-week high price at GBX 307.00 per stock, which the companyâs stock achieved on August 13, 2019. While this piece was being written, the market capitalisation of the company was valued at GBP 719.00 million reportedly, with respect to, the share price of the company at the time of writing.
The beta of the companyâs stock has stood at a value of 0.8582. This enables us to understand the fact that movement in the price of the stock of the company, is less volatile, in comparison with the movement of the comparative benchmark index.
Glencore Plc
Glencore Plc (LON:GLEN) is a Baar, Switzerland based Mining company, that is among the worldâs leading diversified natural resource organisations, primarily engaged in the business of production and distribution of minerals and metals, crude oil and oil products, coal and agricultural products. The company currently operates in more than 50 countries and has an employee base of 158,000, including contractors. The company is currently managing over 150 mines across the globe.
GLEN Price of the stock Performance
As on 6th December 2019, at 01:15 P.M Greenwich Mean Time, while this was being written, Glencore Plcâs price of the stock has been reported to be trading at GBX 216.65 per stock, a decline in the value of 0.12 per cent or GBX 0.25 per stock, in comparison with the last dayâs closing share price, which has been reported to be at GBX 216.90 per stock. At the time of writing, the stock was also trading 37.00 per cent below the 52-week high price at GBX 343.90 per stock, which the companyâs stock achieved on April 17, 2019. While this piece was being written, the market capitalisation of the company was valued at GBP 28.919 billion reportedly, with respect to, the share price of the company at the time of writing.
The beta of the companyâs stock has stood at a value of 2.0963. This enables us to understand the fact that movement in the price of the stock of the company, is more volatile, in comparison with the movement of the comparative benchmark index.
AstraZeneca Plc
AstraZeneca Plc (LON:AZN) is a Cambridge, United Kingdom Domiciled pharmaceutical and Biotechnology organisation. It was established on April 1999 after the merger of Astra AB and Zeneca PL; headquartered at Cambridge, United Kingdom. The company is listed on London, New York and Stockholm exchanges, with the symbol AZN used in all the markets. The company has operations all over the world with business in over 100 countries, and its medicines are consumed by millions of patients across the globe. The company core team works with the worldâs leading academic, biotech research institutions and have a clinical collaboration with Immunomedics.
AZN Price of the stock Performance
As on 6th December 2019, at 01:20 P.M Greenwich Mean Time, while this was being written, AstraZeneca Plcâs price of the stock has been reported to be trading at GBX 7248.00 per stock, an increase in the value of 0.26 per cent or GBX 19.00 per stock, in comparison with the last dayâs closing share price, which has been reported to be at GBX 7229.00 per stock. At the time of writing, the stock was also trading 11.91 per cent below the 52-week high price at GBX 8227.88 per stock, which the companyâs stock achieved on October 07, 2019. While this piece was being written, the market capitalisation of the company was valued at GBP 94.838 billion reportedly, with respect to, the share price of the company at the time of writing.
The beta of the companyâs stock has stood at a value of 0.7989. This enables us to understand the fact that movement in the price of the stock of the company, is less volatile, in comparison with the movement of the comparative benchmark index.
Barclays Plc
Barclays Plc (LON:BARC) is a global financial services provider offering personal and business banking, wholesale and commercial banking, and private and investment banking solutions to individuals, SMEs, corporates, and high-net-worth clients. It offers deposits and accounts, cards, loans, and investment solutions. The bank also offers services such as foreign exchange, transactional lending, mobile banking, premier banking, international banking, and online banking. Barclays caters to retail customers, small to medium-sized enterprises, and large corporates. The bank operates across the Americas, Asia, the Middle East, Europe, and Africa.
BARC Price of the stock Performance
As on 6th December 2019, at 01:25 P.M Greenwich Mean Time, while this was being written, Barclays Plcâs price of the stock has been reported to be trading at GBX 168.89 per stock, an increase in the value of 1.03 per cent or GBX 1.73 per stock, in comparison with the last dayâs closing share price, which has been reported to be at GBX 167.16 per stock. At the time of writing, the companyâs stock was also trading 4.14 per cent below the 52-week high price at GBX 176.19 per stock, which the companyâs stock achieved on November 28, 2019. Â While this piece was being written, the market capitalisation of the company was valued at GBP 28.942 billion reportedly, with respect to, the share price of the company at the time of writing.
The beta of the companyâs stock has stood at a value of 0.8187. This enables us to understand the fact that movement in the price of the stock of the company, is less volatile, in comparison with the movement of the comparative benchmark index.
Comparative Share Price Chart of HICL, PRTC, GLEN, AZN and BARC
(Source: Thomson Reuters) Daily Chart as on 06-December-19, prior to the close of the market
